Back

The unrecognized burden of HFpEF in pacemaker patients: results from a systematic heart failure program

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias Antibradycardia Pacing EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Miss Elisabeth Santos

Unidade local de Saude Gaia/Espinho EPE, Vila Nova de Gaia (Portugal)

146 More presentations in this session

Presentation thumbnail
Impact of ICD and CRT-D implantation on survival in ischemic and non-ischemic cardiomyopathy: a single-center croatian retrospective cohort study and comparative insights with the DANISH trial
Assistant Professor M. Puljevic (Zagreb, HR)
Abstract
Presentation thumbnail
Do the longer leadless pacemakers with helix screws affect tricuspid regurgitation after pacemaker implantation?
Presentation thumbnail
Classification of atrial fibrillation burden pattern in cardiac implantable electronic devices
Mr S. Majumder (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Life-threatening arrhythmia in patients with suspected acute myocarditis
Miss K. Bulatova (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Early outcomes of left bundle branch area pacing upgrade in pediatric pacing-induced cardiomyopathy
Mr Y. Turubayev (Astana, KZ)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Improving HFpEF diagnosis in pacemaker patients: a call for structured screening
thumbnail
Congress Presentation
Comparing diagnostic accuracy of HFA-PEFF score vs. ESC guidelines definition of heart failure with preserved ejection fraction: findings from a pacemaker systematic screening program
thumbnail
Congress Presentation
Heart failure with preserved ejection fraction and incidence rate of atrial fibrillation: insights from a randomized clinical trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources